Steven H. Doares PhD

Steve Doares has been at Cellectis since July 2020 as SVP, US Manufacturing. He is accountable for completing, starting up, and operating Cellectis’ new state-of-the-art drug substance/drug product manufacturing plant for allogeneic T-cell therapies, located in Raleigh, NC. Prior to Cellectis, Steve spent 10 years at Biogen in Manufacturing Sciences, for his last three years there leading the Global Manufacturing Sciences team. He was accountable for technology transfer, technical operations support, and process analytics for Biogen’s clinical and commercial portfolios of biologic, small molecule, and gene therapy programs at both internal manufacturing sites and at CDMOs. Before Biogen, he spent 15 years at Wyeth/Pfizer working primarily in process development and technology transfer of glycoconjugate vaccines. His experience there ranged from bench-scale development work to GMP pilot plant scale-up of vaccine candidates, to staffing and running Wyeth/Pfizer’s full-scale GMP clinical production facility for vaccines in Sanford, NC.